1. Metcalfe DD. Mast cells and mastocytosis. Blood 2008; 112: 946-56.
2.
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 2022; 36: 1703-19.
3.
Sandru F, Petca RC, Costescu M, et al. Cutaneous mastocytosis in childhood – update from the literature. J Clin Med 2021; 10: 1474.
4.
Valent P, Akin C, Sperr WR, et al. Diagnosis and treatment of systemic mastocytosis: state of the art. Br J Haematol 2003; 122: 695-717.
5.
Valent P, Akin C, Metcalfe DD. Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. Blood 2017; 129: 1420-7.
6.
Valent P, Hoermann G, Bonadonna P, et al. The normal range of baseline tryptase should be 1 to 15 ng/ml and covers healthy individuals with HαT. J Allergy Clin Immunol Pract 2023; 11: 3010-20.
7.
Zanotti R, Lombardo C, Passalacqua G, et al. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. J Allergy Clin Immunol 2015; 136: 135-9.
8.
Dawicka J, Lange M, Wasąg B, et al. Rola mutacji genu KIT w etiopatogenezie mastocytozy u dzieci. Przegl Dermatol 2015; 102: 37-44.
9.
Valent P, Akin C, Hartmann K, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. HemaSphere 2021; 5: E646.
10.
Valent P, Akin C, Gleixner KV, et al. Multidisciplinary challenges in mastocytosis and how to address with personalized medicine approaches. Int J Mol Sci 2019; 20: 2976.
11.
Gülen T, Hägglund H, Dahlén B, Nilsson G. Mastocytosis: the puzzling clinical spectrum and challenging diagnostic aspects of an enigmatic disease. J Intern Med 2016; 279: 211-28.
12.
Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med 2012; 18: 693-704.
13.
Simons FER. Anaphylaxis. J Allergy Clin Immunol 2010; 125 (2 Suppl. 2): S161-81.
14.
Valent P. Risk factors and management of severe life-threatening anaphylaxis in patients with clonal mast cell disorders. Clin Exp Allergy 2014; 44: 914-20.
15.
Niedoszytko M, Gorska A, Brockow K, et al. Prevalence of hypersensitivity reactions in various forms of mastocytosis: a pilot study of 2485 adult patients with mastocytosis collected in the ECNM registry. Allergy 2024; 79: 2470-81.
16.
Romantowski J, Górska A, Niedoszytko M, et al. A challenge for allergologist: application of allergy diagnostic methods in mast cell disorders. Int J Mol Sci 2021; 22: 1454.
17.
Bent RK, Varsanova I, Faihs V, et al. Safety and low incidence of anaphylaxis in performing oral drug and food challenges in mastocytosis. J Allergy Clin Immunol Pract 2025; 13: 407-17.
18.
Sturm GJ, Arzt-Gradwohl L, Varga EM. Medical algorithms: diagnosis and treatment of Hymenoptera venom allergy. Allergy 2019; 74: 2016-8.
19.
Smiljkovic D, Kiss R, Lupinek C, et al. Microarray-based detection of allergen-reactive IgE in patients with mastocytosis. J Allergy Clin Immunol Pract 2020; 8: 2761-8.
20.
Blank S, Seismann H, Michel Y, et al. Api m 10, a genuine A. mellifera venom allergen, is clinically relevant but underrepresented in therapeutic extracts. Allergy 2011; 66: 1322-9.
21.
Stoevesandt J, Sturm GJ, Bonadonna P, et al. Risk factors and indicators of severe systemic insect sting reactions. Allergy 2020; 75: 535-45.
22.
Vos BJPR, van Anrooij B, van Doormaal JJ, et al. Fatal anaphylaxis to yellow jacket stings in mastocytosis: options for identification and treatment of at-risk patients. J Allergy Clin Immunol Pract 2017; 5: 1264-71.
23.
Santos AF, Alpan O, Hoffmann HJ. Basophil activation test: mechanisms and considerations for use in clinical trials and clinical practice. Allergy 2021; 76: 2420-32.
24.
Niedoszytko M, De Monchy J, Van Doormaal JJ, et al. Mastocytosis and insect venom allergy: diagnosis, safety and efficacy of venom immunotherapy. Allergy 2009; 64: 1237-45.
25.
Kempinski K, Niedoszytko M. The use of omalizumab beyond asthma and urticaria. Alergia Astma Immunologia 2015; 20: 223-30.
26.
Galera C, Soohun N, Zankar N, et al. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009; 19: 225-9.
27.
Pałgan K, Bartuzi Z, Gotz-Zbikowska M. Treatment with a combination of omalizumab and specific immunotherapy for severe anaphylaxis after a wasp sting. Int J Immunopathol Pharmacol 2014; 27: 109-12.
28.
Lim KH, Tefferi A, Lasho TL, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood 2009; 113: 5727-36.
29.
Jennings S, Russell N, Jennings B, et al. The mastocytosis society survey on mast cell disorders: patient experiences and perceptions. J Allergy Clin Immunol Pract 2014; 2: 70-6.
30.
Cherner JA, Jensen RT, Dubois A, et al. Gastrointestinal dysfunction in systemic mastocytosis: a prospective study. Gastroenterology 1988; 95: 657-67.
31.
Sokol H, Georgin-Lavialle S, Canioni D, et al. Gastrointestinal manifestations in mastocytosis: a study of 83 patients. J Allergy Clin Immunol 2013; 132: 866-73.
32.
Elvevi A, Elli EM, Lucà M, et al. Clinical challenge for gastroenterologists–gastrointestinal manifestations of systemic mastocytosis: a comprehensive review. World J Gastroenterol 2022; 28: 3767-79.
33.
Zanelli M, Pizzi M, Sanguedolce F, et al. Gastrointestinal manifestations in systemic mastocytosis: the need of a multidisciplinary approach. Cancers 2021; 13: 3316.
34.
Lübke J, Naumann N, Hoffmann O, et al. A clinical, morphological and molecular study of 70 patients with gastrointestinal involvement in systemic mastocytosis. Sci Rep 2024; 14: 702.
35.
Bedeir A, Jukic DM, Wang L, et al. Systemic mastocytosis mimicking inflammatory bowel disease: a case report and discussion of gastrointestinal pathology in systemic mastocytosis. Am J Surg Pathol 2006; 30: 1478-82.
36.
Zakharia K, Alsabbak H, Malik A, et al. Gastrointestinal limited mastocytosis, misdiagnosed as Crohn’s disease. Am J Gastroenterol 2017; 112: S835-S836.
37.
Pucino V, Magliacane D, Petraroli A, Triggiani M. Adverse reactions to food in patients with mastocytosis. Clin Transl Allergy 2011; 1 (Suppl 1): P35.
38.
Jarkvist J, Brockow K, Gülen T. Low frequency of IgE-mediated food hypersensitivity in mastocytosis. J Allergy Clin Immunol Pract 2020; 8: 3093-101.
39.
Doyle LA, Sepehr GJ, Hamilton MJ, et al. A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patients. Am J Surg Pathol 2014; 38: 832-43.
40.
Wassmer H, Hartmann K. Mastozytose bei Kindern. Die Dermatologie 2023; 74: 323-9.
41.
Ramsay DB, Stephen S, Borum M, et al. Mast cells in gastrointestinal disease. Gastroenterol Hepatol 2010; 6: 772.
42.
Miner PB. The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis. J Investig Dermatol 1991; 96: S40-4.
43.
Sokol H, Georgin-Lavialle S, Grandpeix-Guyodo C, et al. Gastrointestinal involvement and manifestations in systemic mastocytosis. Inflam Bowel Dis 2010; 16: 1247-53.
44.
Javadi AE, Nazar E, Momeni N. Rare gastrointestinal presentation of systemic mastocytosis, a case report. Ann Med Surg 2022; 80: 104196.
45.
Theoharides TC, Valent P, Akin C. Mast cells, mastocytosis, and related disorders. N Engl J Med 2015; 373: 163-72.
46.
Pardanani A. How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). Blood 2013; 121: 3085-94.
47.
Ottman N, Smidt H, de Vos WM, Belzer C. The function of our microbiota: who is out there and what do they do? Front Cell Infect Microbiol 2012; 2: 104.
48.
Wesolowski J, Paumet F. Escherichia coli exposure inhibits exocytic SNARE-mediated membrane fusion in mast cells. Traffic 2014; 15: 516-30.
49.
Harcęko-Zielińska E, Niedoszytko M, Górska A, et al. The influence of nutritional habits, body mass index and intestinal microbiota in mastocytosis on clinical symptoms using conventional culture and next generation sequencing. Clin Transl Allergy 2024; 14: e12310.
50.
Afrin LB, Khoruts A. Mast cell activation disease and microbiotic interactions. Clin Ther 2015; 37: 941-53.
51.
Brockow K, Jofer C, Behrendt H, Ring J. Anaphylaxis in patients with mastocytosis: a study on history, clinical features and risk factors in 120 patients. Allergy 2008; 63: 226-32.
52.
Brockow K, Ring J, Jofer C. Anaphylaxis in patients with mastocytosis – a prospective study on prevalence, severity and trigger factors in 121 patients. J Allergy Clin Immunol 2006; 117: S307.
53.
Boyce JA, Assa’ad A, Burks AW, et al. Guidelines for the diagnosis and management of food allergy in the United States: summary of the NIAID-sponsored expert panel report. J Allergy Clin Immunol 2010; 126: 1105-18.
54.
Sicherer SH, Sampson HA. Food allergy: a review and update on epidemiology, pathogenesis, diagnosis, prevention, and management. J Allergy Clin Immunol 2018; 141: 41-58.
55.
Spolidoro GCI, Amera YT, Ali MM, et al. Frequency of food allergy in Europe: an updated systematic review and meta-analysis. Allergy 2023; 78: 351-68.
56.
Górska A, Niedoszytko M, Lange M, et al. Risk factors for anaphylaxis in patients with mastocytosis. Pol Arch Med Wewn 2015; 125: 46-53.
57.
Górska A, Gruchała-Niedoszytko M, Niedoszytko M, et al. The role of TRAF4 and B3GAT1 gene expression in the food hypersensitivity and insect venom allergy in mastocytosis. Arch Immunol Ther Exp (Warsz) 2016; 64: 497-503.
58.
Vlieg-Boerstra BJ, van der Heide S, Oude Elberink JNG, et al. Mastocytosis and adverse reactions to biogenic amines and histamine-releasing foods: what is the evidence? Neth J Med 2005; 63: 244-9.
59.
Gulen T, Akin C. Idiopathic anaphylaxis: a perplexing diagnostic challenge for allergists. Curr Allergy Asthma Rep 2021; 21: 11.
60.
Gülen T, Hägglund H, Sander B, et al. The presence of mast cell clonality in patients with unexplained anaphylaxis. Clin Exp Allergy 2014; 44: 1179-87.
61.
Craig A. EAACI guidelines on diagnosis of food allergy: what is new? EMJ Allergy Immunol 2023; 8: 19-21.
62.
Niedoszytko M, Górska A, Brockow K, et al. Prevalence of hypersensitivity reactions in 2485 patients with mastocytosis during 4 year follow up: a study of the ECNM data registry. Allergy 2021; 76: 2470-81.
63.
Loh W, Tang MLK. The epidemiology of food allergy in the global context. Int J Environ Res Public Health 2018; 15: 2043.
64.
Muraro A, Werfel T, Hoffmann-Sommergruber K, et al. EAACI Food Allergy and Anaphylaxis Guidelines: diagnosis and management of food allergy. Allergy 2014; 69: 1008-25.
65.
Pajno GB, Fernandez-Rivas M, Arasi S, et al. EAACI Guidelines on allergen immunotherapy: IgE-mediated food allergy. Allergy 2018; 73: 799-815.
66.
Muraro A, de Silva D, Halken S, et al. Managing food allergy: GA2LEN guideline 2022. World Allergy Organ J 2022; 15: 100687.
67.
Santos AF, Riggioni C, Agache I, et al. EAACI guidelines on the diagnosis of IgE-mediated food allergy. Allergy 2023; 78: 3057-76.
Copyright: © Polish Society of Allergology This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial-No Derivatives 4.0 International (CC BY-NC-SA 4.0). License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
